Annika Kim Constantino
Health and Pharmaceutical Reporter at CNBC
health & pharmaceutical reporter @cnbc | signal: annikakimc.14 | @ucberkeley & @dailycal alum
Articles
-
1 week ago |
cnbc.com | Annika Kim Constantino |Ashley Capoot
A combination image shows an injection pen of Zepbound, Eli Lilly's weight loss drug, and boxes of Wegovy, made by Novo Nordisk. Hollie Adams | ReutersA version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Despite last week's investor jitters, Eli Lilly is far from losing its strong grip on the booming weight loss market.
-
1 week ago |
cnbc.com | Annika Kim Constantino
US President Donald Trump speaks during a cabinet meeting in the Cabinet Room of the White House in Washington, DC, on April 30, 2025. President Donald Trump on Monday signed an executive order to incentivize drug manufacturing in the U.S., streamlining the path for pharmaceutical companies to build new production sites stateside.
-
2 weeks ago |
cnbc.com | Annika Kim Constantino
CEO of Eli Lilly and Company David Ricks speaks at the Economic Club of New York on March 12, 2024 in New York City. Eli Lilly CEO Dave Ricks on Thursday said the drugmaker can help "respond" to national security concerns around cheaper essential medicines as pharmaceutical-specific tariffs loom.
-
2 weeks ago |
cnbc.com | Annika Kim Constantino
The Eli Lilly & Co. logo at the company's Digital Health Innovation Hub facility in Singapore, on Thursday, Nov. 14, 2024. Eli Lilly on Thursday reported first-quarter revenue and earnings that topped estimates as demand for its weight loss and diabetes drugs soared, but lowered its full-year profit guidance due to charges related to a recent cancer treatment deal.
-
2 weeks ago |
nbcchicago.com | Annika Kim Constantino
• CVS Health reported first-quarter revenue and profit that topped estimates and hiked its guidance, as its troubled insurance business showed some improvement during the period. • The company now expects full-year adjusted earnings of $6 to $6.20 per share, up from a previous guidance of $5.75 to $6 per share.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 1K
- Tweets
- 381
- DMs Open
- Yes
Trump just signed an executive order that aims to lower drug costs by reviving the "most favored nation" policy. Part of the #MFN order takes aim at the drug pricing negotiations between other developed nations and pharma. Details here @cnbc: https://t.co/bO41QGEAgl
RT @sherman4949: Scoop: The Comcast spinoff of most of its cable network portfolio (and a handful of digital assets) will be called Versan…
SCOOP on the statuses of seven minority health offices across HHS following RFK Jr.'s massive cuts. That includes NIMHD and offices at the FDA, CDC, HRSA, SAMHSA, and CMS, most of which are completely gutted. Details on the cuts/the consequences @CNBC: https://t.co/x5jScD5dLb